Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastics, daunorubicin derivatives | 2805 | 56124-62-0 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 25, 1998 | FDA | ENDO PHARM |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bladder instillation procedure | 121.36 | 81.78 | 10 | 64 | 0 | 34956857 |
Urge incontinence | 90.55 | 81.78 | 11 | 63 | 539 | 34956318 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bladder instillation procedure | 142.82 | 82.61 | 11 | 62 | 0 | 79744315 |
Urge incontinence | 101.59 | 82.61 | 12 | 61 | 1096 | 79743219 |
None
Source | Code | Description |
---|---|---|
ATC | L01DB09 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D059005 | Topoisomerase II Inhibitors |
MeSH PA | D059003 | Topoisomerase Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Malignant tumor of urinary bladder | indication | 399326009 | DOID:11054 |
Urinary tract infectious disease | contraindication | 68566005 | |
Bladder muscle dysfunction - overactive | contraindication | 236633002 | |
Rupture of bladder | contraindication | 251925007 | |
Pregnancy, function | contraindication | 289908002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Bladder Surgery | contraindication | ||
Small Capacity Bladder | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.85 | acidic |
pKa2 | 9.66 | acidic |
pKa3 | 10.37 | acidic |
pKa4 | 12.86 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA topoisomerase 2-alpha | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4021144 | VUID |
N0000148597 | NUI |
D02697 | KEGG_DRUG |
4021144 | VANDF |
C0068314 | UMLSCUI |
CHEBI:135876 | CHEBI |
CHEMBL1096885 | ChEMBL_ID |
DB00385 | DRUGBANK_ID |
C016163 | MESH_SUPPLEMENTAL_RECORD_UI |
7750 | INN_ID |
2C6NUM6878 | UNII |
454216 | PUBCHEM_CID |
220725 | RXNORM |
11903 | MMSL |
327252 | MMSL |
7552 | MMSL |
d04356 | MMSL |
007694 | NDDF |
116079002 | SNOMEDCT_US |
387002006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Valrubicin Intravesical Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-101 | SOLUTION, CONCENTRATE | 40 mg | INTRAVESICAL | ANDA | 26 sections |
Valrubicin Intravesical Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-101 | SOLUTION, CONCENTRATE | 40 mg | INTRAVESICAL | ANDA | 26 sections |
Valstar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67979-001 | SOLUTION, CONCENTRATE | 40 mg | INTRAVESICAL | NDA | 26 sections |
Valstar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67979-001 | SOLUTION, CONCENTRATE | 40 mg | INTRAVESICAL | NDA | 26 sections |